Retrospective Study of Invasive Fungal Infections With Filamentous Fungi in Heart Transplant Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Strasbourg, France

About this trial

Invasive filamentous fungal infections (aspergillosis, scedosporiosis, mucormycosis, fusarium wilt) are common and serious in immunocompromised subjects and particularly organ transplant patients. There is little recent data in heart transplantation, particularly on the incidence and risk factors of fungal infections. . It is therefore important to have recent data on incidence, risk and prognostic factors in order to improve the management of this severe complication.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patient ≥18 years old

Heart transplant

Invasive fungal infection with filamentous fungi during the period from January 1, 2008 to December 31, 2022

Invasive aspergillosis

Disqualifiers

Patient having expressed his opposition to participating in the study

Patient not having a liver transplant

Subject under guardianship, curatorship or safeguard of justice.

Trial population

Adult patient ≥18 years old having heart transplant and invasive fungal infection with filamentous fungi during the period from January 1, 2008 to December 31, 2022

Trial design

Design model

Case-control

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

To identify the incidence, risk factors and prognostic factors associated with invasive fungal infections caused by filamentous fungi in heart transplant patients.

1. Incidence: number of cases of invasive fungal infection compared to the number of heart transplant patients per year in the study centers 2. Risk factors: Case-control study. Clinical, microbiological or radiological factors statistically associated with cases of invasive fungal infection compared to controls. 3. Prognostic factors: Clinical, microbiological or radiological factors of invasive fungal infections associated with mortality at the 12th week.

Time frame
Up to 2 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.